Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
This article has been cited by
1Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol
SATOSHI YAMASAKI,AKIKO KADA,HIROKAZU NAGAI,ISAO YOSHIDA,ILSEUNG CHOI,YASUHIKO MIYATA,YURI MIYAZAWA,AKIKO SAITO,HIROMI IWASAKI
The Kurume Medical Journal.2019;66(1)37
[DOI]
2Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review
Gilles A. Salles,Ruth Pettengell,Raul Cordoba,Monika Dlugosz-Danecka,Wojciech Jurczak,Hervé Tilly
Leukemia & Lymphoma.2019;60(7)1610
[DOI]
3Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
David J. Straus,Paul A. Hamlin,Matthew J. Matasar,Maria Lia Palomba,Pamela R. Drullinsky,Andrew D. Zelenetz,John F. Gerecitano,Ariela Noy,Audrey M. Hamilton,Rebecca Elstrom,Brett Wegner,Katy Wortman,David Cella
British Journal of Haematology.2015;168(5)663
[DOI]
4Primary skeletal muscle diffuse large B cell lymphoma: A case report and review of the literature
LIJUAN ZHANG,QUANDE LIN,LINA ZHANG,LIHUA DONG,YUFU LI
Oncology Letters.2015;10(4)2156
[DOI]
5Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review
Ann Colosia,Annete Njue,Peter C. Trask,Robert Olivares,Shahnaz Khan,Adeline Abbe,Rachel Police,Jianmin Wang,Rodrigo Ruiz-Soto,James A. Kaye,Farrukh Awan
Clinical Lymphoma Myeloma and Leukemia.2014;14(5)343
[DOI]
6Primary refractory diffuse large B cell lymphoma in the rituximab era
Clémentine Sarkozy,Bertrand Coiffier
Current Opinion in Oncology.2015;27(5)377
[DOI]
7Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
Benigno C. Valdez,David Murray,Yago Nieto,Yang Li,Guiyun Wang,Richard E. Champlin,Borje S. Andersson
Leukemia & Lymphoma.2012;53(5)973
[DOI]
8Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL
Lamiss Mohamed Abd el Aziz
Medical Oncology.2014;31(11)973
[DOI]
9Management of relapsed/refractory DLBCL
Clémentine Sarkozy,Laurie H. Sehn
Best Practice & Research Clinical Haematology.2018;31(3)209
[DOI]

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal